










Status of Development Pipeline (As of July 26, 2021)

Main Status of Development Pipelines (Oncology)











Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Development Stage				Area	In-house / In-license
			I	II	III	Filed		
OPDIVO Intravenous Infusion (Nivolumab)	Anti-PD-1 antibody	Esophageal cancer (Adjuvant therapy)					JP	In-house (Co-development with Bristol-Myers Squibb)
							KR · TW	
		Urothelial carcinoma (Adjuvant therapy)					JP	
		Cancer of unknown primary					JP	
		Hodgkin's lymphoma (Pediatric)					JP	
		Ovarian cancer					JP	
		Bladder cancer					JP · KR · TW	
		Prostate cancer					JP · KR · TW	
		Hepatocellular carcinoma					JP · KR	
		Pancreatic cancer					JP · KR · TW	
		Biliary tract cancer					JP · KR · TW	
		Virus positive / negative solid carcinoma					JP · KR · TW	
YERVOY Injection* (Ipilimumab)	Anti-CTLA-4 antibody	Gastric cancer					JP · KR · TW	Co-development with Bristol-Myers Squibb
		Esophageal cancer					JP · KR · TW	
		Urothelial cancer					JP · KR · TW	
		Hepatocellular carcinoma					JP · KR · TW	
		Virus positive / negative solid carcinoma					JP · KR · TW	
ONO-7701* (Linrodostat)	IDO1 inhibitor	Bladder cancer					JP · KR · TW	Co-development with Bristol-Myers Squibb
BRAFTOVI Capsules (Encorafenib)	BRAF inhibitor	Thyroid cancer					JP	Pfizer
		Colorectal cancer					KR	
		Melanoma					KR	
MEKTOVI Tablets (Binimetinib)	MEK inhibitor	Thyroid cancer					JP	Pfizer
		Colorectal cancer					KR	
		Melanoma					KR	
ONO-4686*	Anti-TIGIT antibody	Solid tumor					JP	Co-development with Bristol-Myers Squibb
ONO-4482* (Relatlimab)	Anti-LAG-3 antibody	Melanoma					JP	Co-development with Bristol-Myers Squibb
ONO-7807*	Anti-TIM-3 antibody	Solid tumor					JP	Co-development with Bristol-Myers Squibb

★ In combination with OPDIVO.

Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Development Stage				Area	In-house / In-license
			I	II	III	Filed		
ONO-7912 (Devimistat)	Cancer metabolism inhibitor	Pancreatic cancer					JP	Rafael
							KR	
		Acute myeloid leukemia					KR	
ONO-7475	Axl / Mer inhibitor	Solid tumor*					JP	In-house
		Non-small cell lung cancer					JP	
		Acute leukemia					US	
ONO-4059 (Tirabrutinib)	Bruton's tyrosine kinase (BTK) inhibitor	Primary central nervous system lymphoma					US	In-house
ONO-4578*	PG receptor (EP4) antagonist	Colorectal cancer					JP	In-house
		Pancreatic cancer					JP	
		Non-small cell lung cancer					JP	
		Solid tumor, Gastric cancer					JP	
ONO-7911* (Bempegaldesleukin)	PEGylated IL-2	Solid tumor					JP	Co-development with Bristol-Myers Squibb
ONO-7913 (Magrolimab)	Anti-CD47 antibody	Pancreatic cancer*					JP	Gilead Sciences
		Colorectal cancer*					JP	
		Solid tumor					JP	
		Myelodysplastic syndrome					JP	

★ In combination with OPDIVO.

Main Status of Development Pipelines (Other than Oncology)

Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Development Stage				Area	In-house / In-license
			I	II	III	Filed		
ORENCIA SC (Abatacept)	T-cell activation inhibitor	Polymyositis / Dermatomyositis					JP	Co-development with Bristol-Myers Squibb
ONOACT for Intravenous Infusion (Landiolol Hydrochloride)	Short-active selective β_1 blocker	Tachyarrhythmia in low cardiac function (Pediatric)					JP	In-house
VELEXBRU Tablets (Tirabrutinib)	Bruton's tyrosine kinase (BTK) inhibitor	Pemphigus					JP	In-house
		Generalized scleroderma					JP	
Joyclu Intra-articular Injection	Hyaluronic acid-NSAID	Enthesopathy					JP	Seikagaku
ONO-2910	Schwann cell differentiation promoter	Diabetic polyneuropathy					JP	In-house
ONO-2808	S1P5 receptor agonist	Neurodegenerative disease					JP · EU	In-house
ONO-4685	PD-1×CD3 bispecific antibody	Autoimmune disease					JP	In-house
ONO-2909	PG receptor (DP1) antagonist	Narcolepsy					JP	In-house
ONO-7684	FXIa inhibitor	Thrombosis					EU	In-house